Health-related quality of life outcomes and economic burden of inflammatory bowel disease in Japan

References

• BaumgartDCSandbornWJInflammatory bowel disease: clinical aspects and established and evolving therapiesThe Lancet2007369957316411657
   PubMed Web of Science ®Google Scholar
• CheonJHGenetics of inflammatory bowel diseases: a comparison between Western and Eastern perspectivesJ Gastroenterol Hepatol201328222022623189979
   PubMedGoogle Scholar
• MolodeckyNASoonISRabiDMIncreasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic reviewGastroenterology20121421465422001864
   PubMed Web of Science ®Google Scholar
• NgWKWongSHNgSCChanging epidemiological trends of inflammatory bowel disease in AsiaIntest Res201614211111927175111
   PubMed Web of Science ®Google Scholar
• AsakuraKNishiwakiYInoueNHibiTWatanabeMTakebayashiTPrevalence of ulcerative colitis and Crohn’s disease in JapanJ Gastroenterol200944765966519424654
   PubMedGoogle Scholar
• MoritaNTokiSHirohashiTIncidence and prevalence of inflammatory bowel disease in Japan: nationwide epidemiological survey during the year 1991J Gastroenterol199530Suppl 814
   PubMed Web of Science ®Google Scholar
• UenoFNakayamaYHagiwaraEKurimotoSHibiTImpact of inflammatory bowel disease on Japanese patients’ quality of life: results of a patient questionnaire surveyJ Gastroenterol201752555556727470433
   PubMed Web of Science ®Google Scholar
• MatsumotoTYanaiSToyaYUenoMNakamuraSInternet-orientated Assessment of QOL and Actual Treatment Status in Japanese Patients with Inflammatory Bowel Disease: The 3I surveyJ Crohns Colitis20159647748225814388
   PubMedGoogle Scholar
• MahlichJMatsuokaKNakamuraYSruamsiriRThe relationship between socio-demographic factors, health status, treatment type, and employment outcome in patients with inflammatory bowel disease in JapanBMC Public Health201717162328676039
   PubMedGoogle Scholar
• CohenRSkupMOzbayABDirect and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the USJ Med Econ201518644745625728698
   PubMed Web of Science ®Google Scholar
• ItoMTogariTJeong ParkMYamazakiYDifficulties at work experienced by patients with inflammatory bowel disease (IBD) and factors relevant to work motivation and depressionJpn J Health Hum Ecol2008746290310
   Google Scholar
• NasuAYamadaKMoriokaIDifficulties at work and work motivation of ulcerative colitis suffersSangyo Eiseigaku Zasshi201557191825420505
   PubMedGoogle Scholar
• Kantar HealthNational Health and Wellness SurveyPatient-Reported Healthcare InsightsNew YorkKantar Health Available from: http://www.kantarhealth.com/docs/datasheets/kh-national-health-and-wellness-survey.pdfAccessed October 31, 2018
   Google Scholar
• WHO Expert ConsultationAppropriate body-mass index for Asian populations and its implications for policy and intervention strategiesLancet2004363940315716314726171
   PubMed Web of Science ®Google Scholar
• CharlsonMEPompeiPAlesKLMackenzieCRA new method of classifying prognostic comorbidity in longitudinal studies: development and validationJ Chronic Dis19874053733833558716
   PubMedGoogle Scholar
• MaruishMEUser’s Manual for the SF36v2® Health Survey3rd edLincolnQualityMetric, Inc2011
   Google Scholar
• BrazierJRobertsJDeverillMThe estimation of a preference-based measure of health from the SF-36J Health Econ200221227129211939242
   PubMed Web of Science ®Google Scholar
• WaltersSJBrazierJEComparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6DQual Life Res20051461523153216110932
   PubMed Web of Science ®Google Scholar
• ReillyMCZbrozekASDukesEMThe validity and reproducibility of a work productivity and activity impairment instrumentPharmacoeconomics19934535336510146874
   PubMed Web of Science ®Google Scholar
• Mhlw.go.jp [homepage on the Internet]TokyoBasic Survey on Wage Structure. Ministry of Health Labour and Welfare of Japan2011 Available from: http://www.mhlw.go.jp/toukei_hakusho/toukei/Accessed August 3, 2017
   Google Scholar
• LoflandJHPizziLFrickKDA review of health-related workplace productivity loss instrumentsPharmacoeconomics200422316518414871164
   PubMed Web of Science ®Google Scholar
• Ministry of Health Law2013 Fiscal Year Trends of Medical ExpensesTokyo, JapanMinistry of Health, Labor and Welfare2014
   Google Scholar
• Organization for Economic Cooperation and Development (OECD)Length of Hospital Stay (Indicator) Available from: https://data.oecd.org/healthcare/length-of-hospital-stay.htmAccessed March 12, 2018
   Google Scholar
• RidgewayGMccaffreyDMorralABurgetteLGriffinBAToolkit for weighting and analysis of nonequivalent groups: a Tutorial for the TWANG PackageSanta Monica, CARAND corporation2017
   Google Scholar
• McCaffreyDFGriffinBAAlmirallDSlaughterMERamchandRBurgetteLFA tutorial on propensity score estimation for multiple treatments using generalized boosted modelsStat Med201332193388341423508673
   PubMed Web of Science ®Google Scholar
• ZandAvan DeenWKInserraEKPresenteeism in inflammatory bowel diseases: a hidden problem with significant economic impactInflamm Bowel Dis20152171623163026070004
   PubMed Web of Science ®Google Scholar
• WillietNSarterHGower-RousseauCPatient-reported outcomes in a French Nationwide Survey of Inflammatory Bowel Disease PatientsJ Crohns Colitis201711216517427516406
   PubMedGoogle Scholar
• van DeenWKvan OijenMGHMyersKDA nationwide 2010–2012 analysis of U.S. healthcare utilization in inflammatory bowel diseasesInflamm Bowel Dis201420101747175325137415
   PubMed Web of Science ®Google Scholar
• BhandariSLarsonMEKumarNSteinDAssociation of inflammatory bowel disease (IBD) with depressive symptoms in the United States population and independent predictors of depressive symptoms in an IBD population: A NHANES StudyGut Liver201711451251928395506
   PubMedGoogle Scholar
• KappelmanMDRifas-ShimanSLPorterCQDirect healthcare costs of Crohn’s disease and ulcerative colitis in US children and adultsGastroenterology200813561907191318854185
   PubMed Web of Science ®Google Scholar
• GibsonTBNgEOzminkowskiRJThe direct and indirect cost burden of Crohn’s disease and ulcerative colitisJ Occup Environ Med200850111261127219001952
   PubMed Web of Science ®Google Scholar
• Mhlw.go.jp [homepage on the Internet]Tokyooutline of health, labour and welfare statistics. Director-general for statistics and information policy, Ministry of Health, Labour and Welfare of Japan2017 Available from: https://www.mhlw.go.jp/toukei/youran/aramashi/shibou.pdfAccessed August 3, 2017
   Google Scholar
• Kantar HealthThe Global Health and Wellness Report2017 Available from: http://www.kantarhealth.com/docs/reports/final-2017-ghwr-full.pdfAccessed March 12, 2018
   Google Scholar
• LichtigerSBinionDGWolfDCThe CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapyAliment Pharmacol Ther201032101228123920955442
   PubMed Web of Science ®Google Scholar
• XuJLinHFengXTangMShenJRanZDifferent therapeutic approaches on quality of life in patients with inflammatory bowel diseaseBMC Gastroenterol201414119925421821
   PubMedGoogle Scholar
• WatersHCVanderpoelJENejadnikBResource utilization before and during infliximab therapy in patients with inflammatory bowel diseaseJ Med Econ20121514552
   PubMedGoogle Scholar
• SaroCCeballosDMuñozFResources utilization and costs the year before and after starting treatment with adalimumab in Crohn’s disease patientsInflamm Bowel Dis20152171631164025961910
   PubMedGoogle Scholar
• LöwenbergMDuijvisNWPonsioenCvan den BrinkGRFockensPD’HaensGRLength of hospital stay and associated hospital costs with infliximab versus cyclosporine in severe ulcerative colitisEur J Gastroenterol Hepatol201426111240124625171024
   PubMedGoogle Scholar